Abstract
This paper reports on results of the EORTC protocol 30892, an open, prospective, randomized study of 310 patients with previously untreated metastatic prostate cancer with favourable prognostic factors who were treated by either flutamide (FLU) or cyproterone acetate (CPA) monotherapy. The final analysis with regard to the main end points, time to progression and survival are still pending. Final results related to the evaluation of sexual functioning prior to and under treatment are reported here. Of 310 randomized patients 294 were eligible for evaluation within this side study. The median age was 71 years (range 48–85). Potential risk factors related to age, general health and prostate cancer were evaluated. For evaluation of sexual functions a five-item questionnaire was used which was administered by the investigator. The protocol allowed time dependent observations at 3-monthly follow-up visits. Sexual functioning was dependent on age but not on prostate cancer-related parameters. Sexual functions at entry were similar within the two treatment groups, spontaneous (nightly) erections and sexual activity were seen in 43–51% and 29–35% of cases. Under treatment, sexual functions under FLU and CPA declined slowly with median times of 12.9 and 5.8 months versus 13.7 and 8.9 months respectively for spontaneous erections and sexual activity. Eventually, with an average observation time in excess of 2 years, loss of spontaneous erections and of sexual activity occurred in 80% versus 92% and in 78% versus 88% of men under FLU versus CPA treatment respectively. None of these differences reached statistical significance. Maintenance of potency under treatment with FLU as reported in the literature is not confirmed in this study. However, loss of sexual functions under monotherapy with both antiandrogens is slow and 10–20% of men retain sexual activity after 2–6 years of treatment. This observation can be exploited in new treatment schemes and is likely to lead to improved quality of life. The advantage of FLU in time and total preservation of sexual functions is statistically not significant and must be balanced against the side effects of FLU and other pure antiandrogens, which may exceed those of CPA especially with respect to gynaecomastia. Hepatic toxicity may limit the long-term use of both drugs. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Agresti A (1990) Categorical Data Analysis. John Wiley & Sons: New York
Ahrens R (1990) Erfahrungen mit Cyproteronacetat bei Patienten mit Sexualdelinquenz. In: Zur Therapie von sexuell Devianten, Wille R, Schumacher W, Andrzejak N (eds), pp.. 58–81. Diesbach Verlag: Berlin
Armitage P (1995) Test for linear trend in proportions and frequencies. Biometrics 11: 375–386
Blackledge GP (1996) High-dose bicalutamide monotherapy for the treatment of prostate cancer. Urology 47: 44–47
Boccon-Gibod L (1998) Are non-steroidal antiandrogens appropriate as monotherapy in advanced prostate cancer?. Eur Urol 33: 159–162
Dalesio O, Schröder FH and Peto R the Prostate Cancer Trialists’ Collaborative Group (1995) Maximal androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3289 deaths in 5710 patients. Lancet 346: 265–269
Diokno AC, Brown MB and Herzog AR (1990) Sexual function in the elderly. Arch Intern Med 150: 197
Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ, Wilding G, Sears K, Culkin DJ, Thompson IM, Bueschen AJ and Lowe BA (1998) Bilateral orchiectomy with or without Flutamide for metastatic prostate cancer. N Engl J Med 339: 1036–1042
Ellis WJ and Grayhack JT (1963) Sexual function in aging males after orchiectomy and estrogen therapy. J Urol 89: 895–899
Feldman HA, Goldstein I, Hatzichristou DG and Krane RJ McKinlay JB (1994) Impotence and its medical and psychosocial correlates: results of the Massachusettes male aging study. J Urol 151: 54–61
Fitzpatrick JM, Kirby RS, Krane RJ, Adolfsson J, Newling DWW and Goldstein I (1998) Sexual dysfunction associated with the management of prostate cancer. Eur Urol 33: 513–522
Frenken J (1978) SBS seksualiteit belevingsshalen; vragenlijst voor de man. In: Frenken J, Vennix P (eds), pp. 20. Swets & Zeitlinger: Lisse
Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD and Akakura K (1995) Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology 45: 839–845
Helgason AR, Arver S, Adolfsson J, Dickman P, Granath F and Steineck G (1998) ‘Potency’. The validation of information from a self-administrated questionnaire using objective measurements of night-time erections and test–retest reliability. Br J Urol 81: 135–141
Jacobi GH, Altwein JE, Kurth KH, Basting R and Hohenfellner R (1980) Treatment of advanced prostatic cancer with parenteral Cyproterone acetate: a phase III randomised trial. Br J Urol 52: 208–215
Kaplan EL and Meier P (1958) Non parametric estimation from incomplete observations. J Am Statist Ass 583: 457–481
Lund F and Rasmussen F (1988) Flutamide versus Stilbestrol in the management of advanced prostatic cancer. Br J Urol 61: 140–142
Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50: 163–170
Morley JE (1988) Impotence in older men. Hospital Practice 23: 139
Pavone-Macaluso M, Voogt HJde, Viggiano G, Barasolo E, Lardennois B, de Pauw M and Sylvester R (1986) Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological Group. J Urol 136: 624–631
Robinson MRG, Smith PH, Richards B, Newling DWW, Pauw M de and Sylvester R (1995) The final analysis of the EORTC Genito-Urinary Group Phase III clinical trial (Protocol 30805) comparing orchidectomy, orchidectomy plus cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate. Eur Urol 28: 273–283
Schröder FH, Whelan P, Kurth KH, Sylvester R and de Pauw M members of the EORTC Genitourinary Group (1997) Antiandrogens as monotherapy for metastatic prostate cancer: a preliminary report on EORTC protocol 30892. Recent Advances in Prostate Cancer and BPH, Proceedings of the IV Congress on Progress and Controversies in Oncological Urology (PACIOU IV), held in Rotterdam, The Netherlands, 11–13 April 1996, Schröder FH (ed), pp. 141–146. Parthenon: New York
Sogani PC, Minoo R, Vagaiwala R and Whitmore WS (1984) Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy. Cancer 54: 744–750
Stenman UH, Hakama M, Knekt P, Aromaa A, Teppo L and Leinonen J (1994) Serum concentrations of prostate specific antigen and its complex with 1-antichymotrypsin before diagnosis of prostate cancer. Lancet 344: 1594–1598
The Medical Research Council Prostate Cancer Working Party Investigators Group (1997) Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br J Urol 79: 235–246
Voogt HJ de, Studer U, Schröder FH, Klijn JG, Pauw M de and Sylvester R members of the EORTC Genito-Urinary Tract Cancer Cooperative Group (1998) Maximum androgen blockade using LHRH agonist Buserelin in combination with short-term (two weeks) or long-term (continuous) Cyproterone-Acetate (CPA) is not superior to standard androgen deprivation in the treatment of advanced prostate cancer. (Final analysis of EORTC GU group trial 30843.). Eur Urol 33: 152–158
Author information
Authors and Affiliations
Consortia
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Schröder, F., Collette, L., de Reijke, T. et al. Prostate cancer treated by anti-androgens: is sexual function preserved?. Br J Cancer 82, 283–290 (2000). https://doi.org/10.1054/bjoc.1999.0916
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1054/bjoc.1999.0916
Keywords
This article is cited by
-
Intermittent versus continuous cyproterone acetate in bone metastatic prostate cancer: results of a randomized trial
World Journal of Urology (2014)
-
Definitive radiotherapy with adjuvant long-term antiandrogen treatment for locally advanced prostate cancer: health-related quality of life and hormonal changes
Prostate Cancer and Prostatic Diseases (2009)
-
Antiandrogen treatments in locally advanced prostate cancer: are they all the same?
Journal of Cancer Research and Clinical Oncology (2006)
-
Prostate Cancer in the Elderly
International Urology and Nephrology (2005)
-
Iatrogénie Sexuelle des Médicaments: conduite à tenir
Andrologie (2005)
